ArticleNPJ digital medicine2026
Towards interpretable prediction of recurrence risk in breast cancer using pathology foundation models.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Transcriptomic assays such as the PAM50-based ROR-P score guide recurrence risk stratification in non-metastatic, ER-positive, HER2-negative breast cancer but are not universally accessible. Histopathology is routinely available and may offer a scalable alternative. We introduce MAKO, a benchmarking framework evaluating 12 pathology foundation models and two non-pathology baselines for predicting ROR-P scores from H&E-stained whole-slide images using attention-based multiple instance learning. Foundation models, large neural networks pre-trained on millions of pathology images and adaptable to diverse downstream tasks, were trained and validated on the Carolina Breast Cancer Study and externally tested on TCGA BRCA. Several foundation models outperformed baseline models across classification, regression, and survival tasks. CONCH achieved the highest ROC AUC, while H-optimus-0 and Virchow2 showed the top correlation with continuous ROR-P scores. All pathology models stratified CBCS participants by recurrence similarly to transcriptomic ROR-P. Using the HIPPO interpretability method, we found that tumor regions were necessary and sufficient for high-risk predictions, and we identified candidate tissue biomarkers of recurrence. These results highlight the promise of interpretable, histology-based risk models in precision oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.